{"product_id":"molecular-aspects-of-aging-9781118396247","title":"Molecular Aspects of Aging","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eMolecular Aspects of Aging: Understanding Lung Aging covers recent research in the mechanisms that contribute to cellular senescence.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eContributors xi\u003c\/p\u003e \u003cp\u003ePreface xiii\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 The Demography of Aging 1\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eDavid E. Bloom and Sinead Shannon\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.1 Introduction 1\u003c\/p\u003e \u003cp\u003e1.2 Demographic trends 1\u003c\/p\u003e \u003cp\u003e1.2.1 Fertility rates 2\u003c\/p\u003e \u003cp\u003e1.2.2 Mortality rates and life expectancy 2\u003c\/p\u003e \u003cp\u003e1.2.3 Proportion of older people 3\u003c\/p\u003e \u003cp\u003e1.3 Impact of aging 4\u003c\/p\u003e \u003cp\u003e1.3.1 Noncommunicable disease trends 4\u003c\/p\u003e \u003cp\u003e1.3.2 Risk factors 5\u003c\/p\u003e \u003cp\u003e1.3.3 Impact of NCDs on health and disability 6\u003c\/p\u003e \u003cp\u003e1.3.4 Increase in multimorbidities 7\u003c\/p\u003e \u003cp\u003e1.3.5 Impact on expenditure 7\u003c\/p\u003e \u003cp\u003e1.4 Policy responses 8\u003c\/p\u003e \u003cp\u003e1.4.1 Preventing and managing NCDs 8\u003c\/p\u003e \u003cp\u003e1.4.2 Promoting exercise 9\u003c\/p\u003e \u003cp\u003e1.4.3 Monitoring health-risk behaviors (and chronic health conditions) 9\u003c\/p\u003e \u003cp\u003e1.5 Conclusion 9\u003c\/p\u003e \u003cp\u003eReferences 10\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 The Omics of Aging: Insights from Genomes upon Stress 13\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eIsmene Karakasilioti, Anna Ioannidou, and George A. Garinis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.1 Introduction 13\u003c\/p\u003e \u003cp\u003e2.2 Safeguarding the nuclear genome 14\u003c\/p\u003e \u003cp\u003e2.3 NER progerias and their connection to lifespan regulatory mechanisms 15\u003c\/p\u003e \u003cp\u003e2.4 Triggering a survival response in the absence of a DNA repair defect 16\u003c\/p\u003e \u003cp\u003e2.5 The omics connection between progeria and longevity 19\u003c\/p\u003e \u003cp\u003e2.6 Triggering of systemic versus cell-autonomous features of the survival response 20\u003c\/p\u003e \u003cp\u003e2.7 The omics connection between NER progeria, transcription, and longevity 21\u003c\/p\u003e \u003cp\u003e2.8 Future perspectives 22\u003c\/p\u003e \u003cp\u003eReferences 22\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Protein Quality Control Coming of Age 27\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eSilke Meiners\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.1 Introduction 27\u003c\/p\u003e \u003cp\u003e3.2 The aging molecular chaperone network 29\u003c\/p\u003e \u003cp\u003e3.3 Protein degradation pathways in aging 30\u003c\/p\u003e \u003cp\u003e3.3.1 Lysosomal autophagy pathway 30\u003c\/p\u003e \u003cp\u003e3.3.2 Ubiquitin–proteasome system 32\u003c\/p\u003e \u003cp\u003e3.4 Compartment-specific protein quality control 34\u003c\/p\u003e \u003cp\u003e3.4.1 The aging ER stress response 34\u003c\/p\u003e \u003cp\u003e3.5 Conclusion 35\u003c\/p\u003e \u003cp\u003eReferences 35\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Telomerase Function in Aging 41\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eRodrigo T. Calado\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.1 Telomeres 41\u003c\/p\u003e \u003cp\u003e4.2 Telomerase 43\u003c\/p\u003e \u003cp\u003e4.3 Telomeres and human disease 45\u003c\/p\u003e \u003cp\u003e4.3.1 Telomere dysfunction in the lungs 46\u003c\/p\u003e \u003cp\u003e4.4 Telomeres biology, aging, and longevity 47\u003c\/p\u003e \u003cp\u003e4.5 Conclusion 48\u003c\/p\u003e \u003cp\u003eReferences 48\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 The Cellular Senescence Program 53\u003c\/b\u003e\u003cbr\u003e \u003ci\u003ePooja Shivshankar and Claude Jourdan Le Saux\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5.1 Cellular senescence and evidence of senescence in a cell 53\u003c\/p\u003e \u003cp\u003e5.1.1 Characteristics of senescent cells and the inflammatory microenvironment 53\u003c\/p\u003e \u003cp\u003e5.1.2 Detection of senescent cells in vitro and in vivo 54\u003c\/p\u003e \u003cp\u003e5.2 Conditions associated with cellular senescence 55\u003c\/p\u003e \u003cp\u003e5.2.1 Oxidative stress 55\u003c\/p\u003e \u003cp\u003e5.2.2 DNA damage 55\u003c\/p\u003e \u003cp\u003e5.2.3 Cell cycle arrest and senescence 56\u003c\/p\u003e \u003cp\u003e5.3 Mechanisms\/pathways of senescence induction 56\u003c\/p\u003e \u003cp\u003e5.3.1 The p53\/p21 pathway 56\u003c\/p\u003e \u003cp\u003e5.3.2 The p16\/pRB pathway 57\u003c\/p\u003e \u003cp\u003e5.3.3 Convergence\/coactivation of p53\/p21 and p16\/pRB pathways 57\u003c\/p\u003e \u003cp\u003e5.3.4 Induction of senescence via molecular signaling 57\u003c\/p\u003e \u003cp\u003e5.4 Cellular senescence in aging and age-related diseases of the lungs 58\u003c\/p\u003e \u003cp\u003e5.4.1 Normal aging 59\u003c\/p\u003e \u003cp\u003e5.4.2 Pneumonia 59\u003c\/p\u003e \u003cp\u003e5.4.3 Chronic obstructive pulmonary disease 60\u003c\/p\u003e \u003cp\u003e5.4.4 Idiopathic pulmonary fibrosis 60\u003c\/p\u003e \u003cp\u003e5.5 Conclusion 61\u003c\/p\u003e \u003cp\u003eReferences 61\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Signaling Networks Controlling Cellular Senescence 67\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eLeena P. Desai, Yan Y. Sanders, and Victor J. Thannickal\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.1 Introduction 67\u003c\/p\u003e \u003cp\u003e6.2 Classification of cellular senescence 69\u003c\/p\u003e \u003cp\u003e6.2.1 Intrinsic pathway 69\u003c\/p\u003e \u003cp\u003e6.2.2 Extrinsic pathway 69\u003c\/p\u003e \u003cp\u003e6.2.3 Reversibility of cellular senescence 70\u003c\/p\u003e \u003cp\u003e6.3 Cross talk of signaling pathways 70\u003c\/p\u003e \u003cp\u003e6.3.1 Protein kinases 70\u003c\/p\u003e \u003cp\u003e6.3.2 Metabolic pathways 71\u003c\/p\u003e \u003cp\u003e6.3.3 Mitochondria and reactive oxygen species 71\u003c\/p\u003e \u003cp\u003e6.3.4 Integrin and focal adhesion signaling 72\u003c\/p\u003e \u003cp\u003e6.3.5 Transforming growth factor-β1 73\u003c\/p\u003e \u003cp\u003e6.3.6 Epigenetic mechanisms 73\u003c\/p\u003e \u003cp\u003e6.4 Conclusion 76\u003c\/p\u003e \u003cp\u003eReferences 77\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Immune Senescence 85\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eKevin P. High\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.1 Introduction 85\u003c\/p\u003e \u003cp\u003e7.2 Barrier defenses and innate immunity in older adults 86\u003c\/p\u003e \u003cp\u003e7.2.1 Barrier defenses 86\u003c\/p\u003e \u003cp\u003e7.2.2 Innate immunity 86\u003c\/p\u003e \u003cp\u003e7.3 Adaptive immune responses 88\u003c\/p\u003e \u003cp\u003e7.3.1 B cell number and function 88\u003c\/p\u003e \u003cp\u003e7.3.2 T cell number, subtypes, and function 89\u003c\/p\u003e \u003cp\u003e7.3.3 T cell activation, differentiation, exhaustion, and senescence 90\u003c\/p\u003e \u003cp\u003e7.4 Consequences of immune senescence 91\u003c\/p\u003e \u003cp\u003e7.4.1 Impaired vaccine responses, increased risk of infection, and age-related illness 91\u003c\/p\u003e \u003cp\u003e7.4.2 Immune senescence: A cause of aging itself 93\u003c\/p\u003e \u003cp\u003e7.5 Conclusion 94\u003c\/p\u003e \u003cp\u003eReferences 95\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Developmental and Physiological Aging of the Lung 99\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eKent E. Pinkerton, Lei Wang, Suzette M. Smiley-Jewell, Jingyi Xu, and Francis H.Y. Green\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.1 Introduction 99\u003c\/p\u003e \u003cp\u003e8.2 The aging lung 99\u003c\/p\u003e \u003cp\u003e8.2.1 Alterations in lung function and anatomy 99\u003c\/p\u003e \u003cp\u003e8.2.2 Oxidative stress and lung antioxidant defenses 101\u003c\/p\u003e \u003cp\u003e8.2.3 Immune system changes with aging 101\u003c\/p\u003e \u003cp\u003e8.2.4 Body mass 102\u003c\/p\u003e \u003cp\u003e8.2.5 Airway receptor and endocrine changes with aging 103\u003c\/p\u003e \u003cp\u003e8.3 An animal model of the aging lung: The rat 104\u003c\/p\u003e \u003cp\u003e8.3.1 The tracheobronchial tree and epithelium of the aging rat 104\u003c\/p\u003e \u003cp\u003e8.3.2 Parenchymal lung structure in the aging rat 105\u003c\/p\u003e \u003cp\u003e8.3.3 Alveolar tissue compartments 106\u003c\/p\u003e \u003cp\u003e8.4 Conclusion 110\u003c\/p\u003e \u003cp\u003eAcknowledgments 110\u003c\/p\u003e \u003cp\u003eReferences 111\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Mouse Models to Explore the Aging Lung 117\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eMingyi Wang and Deepak A. Deshpande\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9.1 Pulmonary changes during aging 117\u003c\/p\u003e \u003cp\u003e9.1.1 Advantages of mouse models for studying physiological lung changes 118\u003c\/p\u003e \u003cp\u003e9.2 Key findings from mouse models of aging 119\u003c\/p\u003e \u003cp\u003e9.2.1 Longevity and lung function in mice 120\u003c\/p\u003e \u003cp\u003e9.2.2 Different strains of mice have different alterations in lung mechanics 120\u003c\/p\u003e \u003cp\u003e9.2.3 Transgenic mouse model to study aging in the lungs 121\u003c\/p\u003e \u003cp\u003e9.3 Age is a risk factor for obstructive pulmonary diseases 123\u003c\/p\u003e \u003cp\u003e9.4 Challenges ahead 124\u003c\/p\u003e \u003cp\u003e9.5 Conclusion 125\u003c\/p\u003e \u003cp\u003eAcknowledgments 126\u003c\/p\u003e \u003cp\u003eReferences 126\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Evidence for Premature Lung Aging of the Injured Neonatal Lung as Exemplified by Bronchopulmonary Dysplasia 131\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eAnne Hilgendorff\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10.1 Introducing bronchopulmonary dysplasia 131\u003c\/p\u003e \u003cp\u003e10.2 Altered pulmonary function in infants with BPD 132\u003c\/p\u003e \u003cp\u003e10.3 Response to injury 133\u003c\/p\u003e \u003cp\u003e10.3.1 Oxidative stress response 134\u003c\/p\u003e \u003cp\u003e10.3.2 Extracellular matrix remodeling 136\u003c\/p\u003e \u003cp\u003e10.3.3 Inflammation 136\u003c\/p\u003e \u003cp\u003e10.3.4 Morphogenetic response 137\u003c\/p\u003e \u003cp\u003e10.4 Prenatal and genetic predisposition 137\u003c\/p\u003e \u003cp\u003e10.5 Conclusion 138\u003c\/p\u003e \u003cp\u003eReferences 138\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Remodeling of the Extracellular Matrix in the Aging Lung 145\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eJesse Roman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11.1 Introduction 145\u003c\/p\u003e \u003cp\u003e11.2 The aging lung 145\u003c\/p\u003e \u003cp\u003e11.3 Activation of tissue remodeling in the senescent lung 146\u003c\/p\u003e \u003cp\u003e11.4 The aging lung fibroblast 148\u003c\/p\u003e \u003cp\u003e11.5 Potential role of oxidant stress in triggering remodeling in the aging lung 149\u003c\/p\u003e \u003cp\u003e11.6 Implications for remodeling of the lung extracellular matrix in the aged lung 150\u003c\/p\u003e \u003cp\u003e11.7 Conclusions 152\u003c\/p\u003e \u003cp\u003eAcknowledgments 154\u003c\/p\u003e \u003cp\u003eReferences 154\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Aging Mesenchymal Stem Cells in Lung Disease 159\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eMaria G. Kapetanaki, Ana L. Mora, and Mauricio Rojas\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12.1 Aging and lung diseases 159\u003c\/p\u003e \u003cp\u003e12.2 Mesenchymal stem cells (MSCs) 160\u003c\/p\u003e \u003cp\u003e12.2.1 Description of MSCs 160\u003c\/p\u003e \u003cp\u003e12.2.2 Characterization of MSCs 160\u003c\/p\u003e \u003cp\u003e12.2.3 Functional properties of MSCs 161\u003c\/p\u003e \u003cp\u003e12.3 Impact of aging on mesenchymal stem cells 162\u003c\/p\u003e \u003cp\u003e12.3.1 In vitro aging of MSCs 162\u003c\/p\u003e \u003cp\u003e12.3.2 Age-related changes in B-MSCs 163\u003c\/p\u003e \u003cp\u003e12.3.3 Aging of B-MSCs versus aging of the organism 163\u003c\/p\u003e \u003cp\u003e12.4 B-MSCs in disease 164\u003c\/p\u003e \u003cp\u003e12.5 B-MSCs in therapy 166\u003c\/p\u003e \u003cp\u003e12.5.1 Ex vivo expansion 166\u003c\/p\u003e \u003cp\u003e12.5.2 Conditions affecting the expansion 167\u003c\/p\u003e \u003cp\u003e12.5.3 Autologous versus allogeneic B-MSCs 167\u003c\/p\u003e \u003cp\u003e12.5.4 Combination of cell preparations 167\u003c\/p\u003e \u003cp\u003e12.5.5 Delivery and targeting 167\u003c\/p\u003e \u003cp\u003e12.6 Conclusion 167\u003c\/p\u003e \u003cp\u003eAcknowledgments 168\u003c\/p\u003e \u003cp\u003eReferences 168\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 COPD as a Disease of Premature Aging 173\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eLaurent Boyer, Jorge Boczkowski, and Serge Adnot\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13.1 Introduction 173\u003c\/p\u003e \u003cp\u003e13.2 Senescent cells contribute to the pathogenesis of COPD 174\u003c\/p\u003e \u003cp\u003e13.2.1 Accumulation of senescent cells in COPD lungs 174\u003c\/p\u003e \u003cp\u003e13.2.2 Inflammation and lung-cell senescence in COPD 175\u003c\/p\u003e \u003cp\u003e13.2.3 Emphysema and lung-cell senescence in COPD 176\u003c\/p\u003e \u003cp\u003e13.2.4 Pulmonary hypertension and cell senescence in COPD 177\u003c\/p\u003e \u003cp\u003e13.3 Lung dysfunction and the general process of premature aging in COPD 179\u003c\/p\u003e \u003cp\u003e13.3.1 Clinical manifestations of premature aging in COPD patients 179\u003c\/p\u003e \u003cp\u003e13.3.2 Role for lung alterations in systemic premature aging during COPD 180\u003c\/p\u003e \u003cp\u003e13.4 Conclusion 181\u003c\/p\u003e \u003cp\u003eReferences 181\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Lung Infections and Aging 185\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eJacqueline M. Kruser and Keith C. Meyer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14.1 Introduction 185\u003c\/p\u003e \u003cp\u003e14.2 Aging and immunosenescence 185\u003c\/p\u003e \u003cp\u003e14.2.1 Innate immunity 187\u003c\/p\u003e \u003cp\u003e14.2.2 Adaptive immunity 188\u003c\/p\u003e \u003cp\u003e14.2.3 Autoimmunity 189\u003c\/p\u003e \u003cp\u003e14.2.4 Lung-specific changes in immunity with aging 190\u003c\/p\u003e \u003cp\u003e14.3 Inflamm-aging and susceptibility to infection 190\u003c\/p\u003e \u003cp\u003e14.4 Respiratory infection and regulation of host responses 192\u003c\/p\u003e \u003cp\u003e14.5 Preventing respiratory infection 194\u003c\/p\u003e \u003cp\u003e14.6 Summary and conclusions 195\u003c\/p\u003e \u003cp\u003eReferences 195\u003c\/p\u003e \u003cp\u003eIndex 201\u003c\/p\u003e","brand":"John Wiley and Sons Ltd","offers":[{"title":"Default Title","offer_id":49406863999319,"sku":"9781118396247","price":105.26,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781118396247.jpg?v=1730497375","url":"https:\/\/bookcurl.com\/products\/molecular-aspects-of-aging-9781118396247","provider":"Book Curl","version":"1.0","type":"link"}